Dexamethasone for Neoplasms, Plasma Cell

Neoplasms, plasma cell is one of the peripheral forms of multiple myeloma but it can be found in other plasma cell-related diseases as well. The plasma cells often form multiple myeloma-like disease without causing pain or anemia but they may grow in the bone marrow. Differential diagnosis is required because treatment for plasma cell dysplasias usually is different from multiple myeloma.

The plasma cell is the most frequently involved myeloid neoplasms group in BMACs, which, due to its aggressive biological behavior are associated with high morbidity and mortality. Neoplasms of plasma cell are usually asymptomatic. Patients presenting with plasmacytomas are mostly non-secretory, elderly males, whose prognosis is generally unfavorable, even if treated locally with radiation therapy.

CML is [a progressive disorder] and so its progress toward complete remission in patients with high initial CML numbers cannot be confirmed in a randomized, single-arm trial. However, patients with low initial CML numbers might benefit from the administration of high-dose [Imatinib mesylate, Novartis, Groupe Octexa]http://www.nhs.uk/conditions/cancer/oncology/malignant-tumours/diagnosis/cmo_index/cmo/cmo-index_view.aspx. answer: CML therapy is a treatment option for patients with CML and may possibly represent a cure.

In neoplasms, plasma cell-directed therapies have the best survival rate for the patient; the patients' own immunity is expected to control the disease more effectively. The survival rates and duration of treatment are longest for elderly neoplasm patients, those with multiple and/or early distant metastases, and those who are able to control their disease (e.g., with minimal residual disease after treatment). The survival rate of plasma cell disease increases significantly with the increase of the number of treatment cycles and treatment duration for one neoplasm. The risk of experiencing severe side effects or death increase with the duration of treatment for multiple neoplasms.

The signs of PCL include bone pain, an increased sedimentation rate and enlargement of osseous lesions on radiographs. These signals may become more obvious as the disease advances and become more and more severe. The disease may also cause severe spinal stenosis. Increased sedimentation rate may suggest a greater presence of tumor-related bone lesions.

Although neoplasms and plasma cell-associated neoplasms are the two most common reasons for visits to hospitals, the current data are insufficient to determine their relative frequency during the year in the USA. This problem will be resolved with improved clinical information of neoplasms and plasma cell disorders.

In contrast to a recent study, we were not able to prove dexamethasone's effectiveness as an immune-modulatory drug in malignant and benign tumor patients. We conclude that in clinical settings there is still a lack of evidence concerning dexamethasone's biological activity.

The rapid appearance of neoplasms in the initial stages of cancer evolution might indicate the existence of a very rapidly proliferating population. Alternatively, this rapid growth may be caused by the presence in the plasma cell population of neoplasms. However, these data may be explained by neoplasms or plasma cells as cellular precursors for secondary malignancies.

Neoplasms and plasma cell typically present between 40-60 years old in the UK [NCCN guidelines-2018, UK cancer patient's organization-2019]. [Read more on average age of neoplasms, plasma cell in UK]

Dexamethasone was not associated with better quality of life in those with plasma cell neoplasms. However, patient preferences suggest improvement in QOL with dexamethasone. The role of dexamethasone in the treatment of multiple myeloma needs further study.

In the authors' experience, dexamethasone added to other existing therapies is often used in the treatment of multiple myeloma when patients are initially ineligible to be treated with thalidomide alone or are not responding adequately to thalidomide.